Search PubMed⌕ Search

Biomedical subjects

H KONZETT

Publications and source records attributed to H KONZETT.

At least 37 records · Page 2Linked to original sources
PubMed1959

The biological activity of a new analogue of oxytocin in which the tyrosyl group is replaced by phenylalanyl.

A new synthetic analogue of oxytocin with a phenylalanyl group instead of a tyrosyl group has been investigated. The most prominent biological properties of this peptide were its oxytocic activity on the rat or cat uterus in vivo and on milk-ejection pressure in the rabbit. Another remarkable feature was the striking difference in pressor activity measured in spinal cats and in anaesthetized rats. The presence of the phenylalanyl group in the molecule in the above-mentioned position did not increase the antidiuretic potency in unanaesthetized rats. The authors propose a nomenclature for the peptides related to oxytocin and vasopressin.

Animals↗
PubMed1959

Comparison of effects of valyl(3)-oxytocin and syntocinon on the cardiovascular system of man.

Valyl(3)-oxytocin has similar circulatory effects in man to those of Syntocinon (synthetic oxytocin). On intravenous administration, it caused a rise in limb blood flow and in pulse rate and a fall in blood pressure. It had a direct vasodilator effect on limb blood vessels. Valyl(3)-oxytocin was 1.5 to 2 times more potent than Syntocinon in terms of its circulatory effect in man. The circulatory effects of valyl(3)-oxytocin were less readily antagonized by vasopressin than are those of Syntocinon.

Administration, Intravenous↗
PubMed1957

Some pharmacological actions of four synthetic analogues of oxytocin.

Four structural analogues of oxytocin were investigated with regard to their oxytocic, milk-ejecting, pressor and diuretic/antidiuretic effects. In three of them the isoleucyl group of oxytocin was replaced by a phenylalanyl, leucyl, or valyl residue; in the fourth the asparaginyl group was replaced by a glutaminyl residue. Synthetic oxytocin and the international standard pituitary (posterior lobe) powder were used for comparison. Although the analogues showed marked differences in their oxytocic effects, there was a fairly good agreement between the results obtained on the isolated rat uterus and the blood pressure of the chicken for each polypeptide. The milk-ejection pressure test gave much higher values throughout. The pressor and antidiuretic activities of the four analogues showed no obvious correlation with the values obtained in the other tests. The valyl and the leucyl analogues also had a diuretic effect. The phenylalanyl analogue was remarkable for the close correspondence between its oxytocic and antidiuretic effects: practically identical values were obtained for the potency, whether measured on the rat uterus in vitro, the blood pressure in the chicken, the cat uterus in situ or water diuresis in the rat. The leucyl analogue showed an oxytocic activity on the cat uterus in situ or the rabbit mammary gland roughly 7 to 9 times as high as that measured by means of the conventional bioassay methods, such as the blood pressure of the chicken or the rat uterus in vitro. The glutaminyl analogue, the weakest of the whole series, had only a modest effect on the mammary gland. The valyl analogue was the most interesting of the new polypeptides. Its oxytocic action on the cat uterus in situ and its milk-ejecting effect were greater than that of synthetic oxytocin, whereas its antidiuretic and pressor effects were less. In cats and rats, the uterine effect was stronger in situ than in vitro. There were also distinct species differences between cats, rabbits, and rats in their sensitivity to valyl-oxytocin.

Animals↗